India Microfinance & SFB Stocks 2026: Stress, Recovery & Who Stands Out

India's microfinance and small finance bank (SFB) sector is in the middle of one of its most challenging cycles since the 2010 Andhra Pradesh crisis. Rising household indebtedness among low-income borrowers, overleveraging across multiple lenders, and the lag effect of post-COVID cash-flow disruptions have pushed non-performing assets (NPAs) sharply higher across nearly every player in the space.

Yet stock prices for several names have already recovered meaningfully from their 2025 lows — raising a genuine question: is the worst priced in, or is there more pain ahead? We pulled live data from the DocStoX dataset (sourced from NSE/BSE audited filings) to give you the unfiltered numbers.

The Five Players: Where They Stand Today (July 2026)

Here is the live snapshot across the major listed MFI and SFB names:

• CreditAccess Grameen (CREDITACC): Price ₹1,529 | Market Cap ₹24,513 Cr | P/E 46x | P/B 3.24x | ROE 9.92% | D/E 2.98x
• Ujjivan Small Finance Bank (UJJIVANSFB): Price ₹65 | Market Cap ₹12,670 Cr | P/E 17.4x | P/B 1.78x | ROE 11.94% | PAT ₹726 Cr
• Equitas Small Finance Bank (EQUITASBNK): Price ₹82 | Market Cap ₹9,412 Cr | P/E 63.8x | P/B 1.48x | ROE 2.42%
• Fusion Finance (FUSION): Price ₹234 | Market Cap ₹3,810 Cr | P/B 1.49x | ROE 0.56% | D/E 2.92x
• Spandana Sphoorty (SPANDANA): Price ₹306 | Market Cap ₹2,714 Cr | P/B 1.0x | ROE −39.31% | PAT −₹957 Cr (loss)

The divergence in outcomes is stark. CreditAccess — the largest listed pure-play MFI — remains profitable with a PAT of ₹531 crore and has defended its franchise better than most. Spandana and Fusion have both slipped into losses, with Spandana reporting a PAT of negative ₹957 crore — a sign that the NPA surge has overwhelmed provisioning buffers.

CreditAccess Grameen: The Quality Anchor

CreditAccess Grameen is the only large-cap in this peer set (market cap ₹24,513 crore) and the only one trading at a premium multiple — P/E 46x, P/B 3.24x. That premium is not irrational: CreditAccess has a 10-year compounded sales growth of 29% and a 10-year compounded profit CAGR of 25%, both well above the sector average.

The current ROE of 9.92% is depressed relative to its historical average of 13–14% over 5 years, reflecting elevated provisions in FY25–26. The 52-week price range (₹1,113–₹1,608) shows the stock has largely recovered from the sector sell-off. Its debt-to-equity of 2.98x is high by industrial standards but normal for an NBFC-MFI — leverage is the business model.

The company employs 20,970 people and exclusively serves women borrowers organized into Joint Liability Groups (JLGs) — a model that has historically produced lower defaults than individual microloans. CreditAccess is backed by global MFI operator CreditAccess Asia, which gives it both funding diversification and operational discipline.

Ujjivan SFB: The Best-Placed Recovery Trade

Ujjivan Small Finance Bank is the most interesting risk/reward in the peer group right now. At 17.4x P/E and 1.78x P/B, it is valued far more cheaply than its historical band of 25–35x, yet it remains profitable — PAT of ₹726 crore on an ROE of 11.94%.

Its 52-week range is ₹41–₹68, and the stock is currently near the top of that range (₹65), suggesting the market is beginning to price in a normalisation. The 5-year ROE average of 15% points to significant earnings recovery potential as provisions normalise. Revenue has compounded at 20% over 3 years and 20% over 5 years — the underlying franchise is growing despite the credit stress.

Ujjivan's core differentiator vs pure MFIs: it converted to a small finance bank in 2017, which means it can raise low-cost CASA deposits rather than depending entirely on wholesale borrowings. That reduces funding cost and improves resilience through NPA cycles.

Equitas SFB: Earnings Recovery Lagging

Equitas Small Finance Bank tells a more complicated story. Its P/E of 63.8x looks expensive — but that is a function of collapsed earnings (PAT ₹147 crore, ROE 2.42%), not an inflated share price. The stock has already corrected sharply from its highs; the 52-week low was ₹50 against a current price of ₹82.

The 3-year ROE average of 6% and 5-year of 7% are both below what a bank should earn on equity. Equitas's 10-year revenue CAGR of 32% shows the growth engine is intact, but the conversion from revenue growth to profit has broken down in FY25–26 due to credit costs. Like Ujjivan, it benefits from the SFB model (CASA funding) but has a higher exposure to small business loans (SBL) alongside microfinance — a segment that tends to be more cyclical.

Fusion Finance and Spandana: Restructuring Stories

Fusion Finance and Spandana Sphoorty are best classified as restructuring plays rather than quality compounder bets. Both are trading near or below book value (Spandana at 1.0x P/B, Fusion at 1.49x P/B), which limits downside but signals that the market expects more write-offs.

Spandana's ROE of negative 39.31% and PAT of negative ₹957 crore reflect a severe NPA cycle. Its promoter holding has declined 14.8% over three years — a red flag. However, the stock has recovered 69% from its 52-week low of ₹181 to ₹306 today, suggesting the market is beginning to discount a recovery scenario.

Fusion Finance is in a similar position: ROE at near-zero (0.56%), D/E of 2.92x, and declining revenue (compounded sales growth TTM: −28%). The stock is close to its 52-week high of ₹242 (current ₹234), having bounced 72% from the low of ₹137. Investors betting here are betting on a sector turn, not on company-specific earnings quality.

The Sector Lens: Why This Cycle Is Different

Three structural factors make the 2025–26 MFI stress different from earlier cycles:

1. Overleveraging at the borrower level: RBI data shows average MFI borrower indebtedness in states like Karnataka, Tamil Nadu, and West Bengal has crossed 4–5 lenders per household — far above the 2–3 threshold that historically precedes credit stress events.
2. Regulatory tightening: RBI's 2024–25 guidelines on MFI lending caps (household income-based limits) have compressed disbursement growth industry-wide, reducing the ability of lenders to grow out of the NPA problem.
3. Rural income pressure: Uneven monsoons and delayed government transfer payments in several states in H2 FY25 tightened cash flows for JLG borrowers precisely when NPAs were peaking.

The good news: most of the large-cap MFIs have now built adequate provisioning buffers, and the rate of new slippages appears to be stabilising in Q4 FY26. That is the foundation for an earnings recovery in FY27 — which is what the stock prices are beginning to anticipate.

What to Watch

• Gross NPA trends Q1 FY27 (results due July–August 2026): A sequential decline in GNPA% would be the first hard signal of normalisation
• Collection efficiency: Monthly data from lenders on collection efficiency (CE) — anything consistently above 98% across the portfolio signals stabilisation
• RBI stance on MFI guidelines: Any easing of income-ceiling caps or borrower-count limits would be a direct catalyst for disbursement growth
• CreditAccess ROE trajectory: A return to 13–15% ROE from the current 9.92% is the base case for FY27 — the stock re-rates if that materialises

The DocStoX Take

This is a sector with genuine value — but also genuine risk that is not yet fully resolved. CreditAccess Grameen remains the highest-quality franchise in the MFI space and the safest vehicle for long-term exposure to India's financial inclusion story. Ujjivan SFB is the best-placed recovery trade given its SFB model, reasonable valuations, and maintained profitability.

Spandana and Fusion are speculative recovery bets — possible returns if the cycle turns, but not suitable for conservative portfolios given ongoing losses and weak ROEs.

Equitas sits in between: SFB model provides stability, but the earnings recovery needs to come through before the valuation makes sense at current levels.

Live data, DocStoX AI verdicts, and real-time prices for all five stocks are available at docstox.com.

---

By the DocStoX Desk — This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.